Showing results (1271-1280 of 1,308) with videos related to

Sort By:
Pageof 131
Rheumatology (Oxford, England)|March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritisMichael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
Mutagenesis|March 1, 2013
An ECVAG inter-laboratory validation study of the comet assay: inter-laboratory and intra-laboratory variations of DNA strand breaks and FPG-sensitive sites in human mononuclear cellsClara Ersson, Peter Møller, Lykke Forchhammer, et al.
Mutagenesis|April 17, 2014
Variation of DNA damage levels in peripheral blood mononuclear cells isolated in different laboratoriesRoger W L Godschalk, Clara Ersson, Maciej Stępnik, et al.
Environment International|May 11, 2022
Long-term exposure to air pollution and mortality in a Danish nationwide administrative cohort study: Beyond mortality from cardiopulmonary disease and lung cancerRina So, Zorana J Andersen, Jie Chen, et al.
Rheumatology (Oxford, England)|June 14, 2023
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registriesLouise Linde, Lykke M Ørnbjerg, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|October 31, 2019
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpACecilie Heegaard Brahe, Lykke Midtbøll Ørnbjerg, Lennart Jacobsson, et al.
Annals of the Rheumatic Diseases|August 22, 2019
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Johan Askling, et al.
EULAR Rheumatology Open|June 29, 2026
Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort studyAnnik Steimer, Andrea Götschi, Jonas Brändli, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
The Journal of Rheumatology|February 1, 2025
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration NetworkMarion Pons, Stylianos Georgiadis, Merete Lund Hetland, et al.
Pageof 131